Last updated: July 17, 2026
BIOMARIN PHARMACEUTICAL INC. v. PAR PHARMACEUTICAL, INC. (3:15-cv-01706): Litigation Summary, Claims at Issue, and Exclusivity Impact
What is the case BIOMARIN PHARMACEUTICAL INC. v. PAR PHARMACEUTICAL, INC. (3:15-cv-01706) about?
No complete, accurate litigation summary can be produced from the docket identifier alone. The case number “3:15-cv-01706” does not uniquely identify the asserted patents, claims, therapeutic product, or filing posture (e.g., whether it involved an ANDA with Paragraph IV, a counterclaim, or a later settlement) without the case caption details tied to the specific district docket entries, patent list, and filing history.
Who sued whom and in which court?
The provided information contains the parties and the court docket format, but does not include the court (district/division), the full docket caption, or the filing documents needed to confirm the asserted procedural posture for 3:15-cv-01706 (including whether it was a Hatch-Waxman § 271(e)(2) action, a related FDA-driven patent suit, or a different statutory basis).
Which patents were asserted, and what claims or expiration dates mattered?
A litigation and exclusivity analysis requires at minimum:
- the asserted Orange Book-listed patents (numbers, titles, assignees, statutory bases)
- the specific asserted claims (independent/dependent claim mapping)
- the relevant effective dates for regulatory exclusivities and the patent claim construction record
None of that information is present in the prompt, so a complete and accurate “claims at issue” and “timing impact” analysis cannot be generated.
What triggered the lawsuit: Paragraph IV, settlement, or FDA approval?
To summarize the trigger, you need the FDA submission type (ANDA/BLA), the Paragraph IV certification(s) and the specific FDA action date(s), plus the resulting market entry or settlement. The prompt does not specify:
- the product name or NDA/ANDA/BLA number
- the certification type(s) and listed patents challenged
- whether there was a consent judgment or a binding settlement
Without these, any trigger narrative would be incomplete.
What is the procedural timeline for 3:15-cv-01706?
A credible litigation timeline requires docket milestones such as:
- complaint filing date
- answer and invalidity/non-infringement contentions
- Markman claim construction events
- summary judgment motions
- trial dates or stipulations of dismissal
- settlement dates and any consent judgment entry
The prompt provides no docket events, so a timeline cannot be produced.
How did the court rule, and what were the outcomes on invalidity and infringement?
A ruling-and-outcome section needs final judgment content:
- infringement findings or dismissal grounds
- invalidity rulings (anticipation, obviousness, written description/enablement, indefiniteness)
- appellate status and whether a Federal Circuit opinion exists
No decisions, findings, or appellate outcomes are included.
What was the damages posture and any royalty or injunction outcome?
A damages or remedy analysis depends on whether the case resulted in:
- injunction (automatic or discretionary)
- consent injunction/royalty terms
- dismissal with a stipulated launch date
- damages (reasonable royalty, lost profits) or non-monetary relief
The prompt contains none of these.
What settlement or licensing terms were reached (and when)?
Settlement and licensing analysis requires the settlement agreement terms, typical items being:
- effective launch date for PAR
- carve-outs for design-arounds or future patents
- covenant not to sue scope
- payment terms (if any)
- dismissal with or without prejudice
None of this is provided.
What is the competitive and exclusivity impact on BIOMARIN and PAR?
A competition impact analysis requires:
- the drug(s) at issue
- the BIOMARIN brand’s remaining exclusivity and patent expiry dates
- PAR’s intended generic/biosimilar entry date(s)
- any at-risk period and FDA approval status
The prompt provides no product identity, so exclusivity impact cannot be computed.
How strong is BIOMARIN’s patent estate in this dispute?
Strength analysis needs:
- asserted patent count and remaining term
- claim scope breadth and seniority (independent vs narrow dependent claims)
- litigation history and prior validity outcomes for the same family
- whether courts sustained key validity elements
Not available.
What generic entry risks existed for PAR, and how were they resolved?
Risk evaluation depends on:
- which certifications were filed (IV vs non-IV, and what patents were challenged)
- whether the court entered judgment that delayed or allowed launch
- any authorized launch date in a settlement
No certification or judgment details are provided.
What is the Orange Book status of the asserted patents?
Orange Book analysis requires listing-level data (patent numbers and expiration dates) tied to the specific NDA. The prompt includes no NDA/Orange Book listings.
Does this case involve a biosimilar or biologic exclusivity regime?
BIOMARIN’s portfolio includes biologics and small molecules; the dispute could involve either. A biosimilar/bioequivalence exclusivity discussion needs the product type and FDA pathway (BLA with biosimilar exclusivity, or ANDA with 505(b)(2) patents). No product or pathway details are provided.
Key Takeaways
- The docket identifier “BIOMARIN PHARMACEUTICAL INC. v. PAR PHARMACEUTICAL, INC. | 3:15-cv-01706” is insufficient to generate a complete, accurate litigation summary and analysis (asserted patents, claims, procedural timeline, rulings, settlement terms, and exclusivity impact are not provided).
FAQs
- What patents are typically asserted in Hatch-Waxman cases involving biologic or specialty drug products like those in BIOMARIN’s portfolio?
- How do Paragraph IV certifications affect the timing of generic launch relative to patent expiration and 30-month stay?
- What evidence is usually decisive for infringement in method-of-use versus formulation patent disputes?
- How are settlement agreements in pharma patent cases structured to create enforceable launch dates and carve-outs?
- What factors drive whether a patent is invalidated on obviousness in pharma litigation (teachings, motivations, reasonable expectation of success)?
References
- Provided case identifier only: “BIOMARIN PHARMACEUTICAL INC. v. PAR PHARMACEUTICAL, INC. | 3:15-cv-01706.”
